ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of ... The Herald | HeraldOnline.com "We are encouraged by the evidence of antitumor activity of IGN002 observed in pre-clinical studies in rituximab-resistant tumor models and are preparing for an IND filing for IGN002 in the second half of 2014." About IGN002. IGN002, a fusion molecule ... |
